Chlorhexidine Cord Care Shows Targeted Benefit in Reducing Neonatal Infection Risk in Low-Resource Settings

Efforts to reduce neonatal mortality continue to prioritize simple, scalable interventions—particularly in low- and middle-income countries (LMICs), where infection remains a leading cause of early death. An updated Cochrane systematic review offers a nuanced assessment of one such intervention: the application of antiseptics to the umbilical cord stump. Drawing on data from more than 143,000 newborns across 18 randomized trials, the findings reinforce the role of chlorhexidine while raising important questions about its broader applicability.

The umbilical cord stump, though temporary, represents a critical vulnerability in the neonatal period. As described in the review, it can serve as a portal of entry for pathogenic bacteria, potentially leading to omphalitis and, in severe cases, systemic infection and death . This risk is particularly pronounced in settings with limited access to sterile delivery conditions and postnatal care.

Among the antiseptics evaluated, 4% chlorhexidine (CHX) stands out for its clinical impact in LMICs. Pooled data from five large community-based trials suggest that chlorhexidine likely reduces the incidence of omphalitis, lowering rates from 87 to 62 per 1,000 live births. This effect is supported by moderate-certainty evidence and represents a meaningful reduction in a common and potentially dangerous complication. There is also an indication that chlorhexidine may reduce all-cause neonatal mortality—from 18 to 15 per 1,000 births—though the certainty of this finding remains low due to variability across studies .

These benefits, however, are not without trade-offs. The review consistently found that chlorhexidine delays cord separation by approximately 1.8 days. While this outcome is clinically benign, it may influence caregiver perceptions and practices, particularly in cultures where rapid cord detachment is expected.

In contrast, the evidence for other commonly used antiseptics is far less compelling. Studies evaluating 70% alcohol, silver sulfadiazine, and povidone-iodine yielded either inconclusive or very low-certainty results, particularly with respect to infection prevention. Alcohol, for instance, showed no clear benefit in reducing omphalitis and was associated with a modest delay in cord separation in higher-income settings.

Indeed, one of the most striking aspects of the review is the divergence in effectiveness between LMICs and high-income countries (HICs). In HICs—where hygienic delivery practices and postnatal care are more standardized—the evidence does not support a clear benefit for antiseptic cord care over dry cord care. The baseline risk of infection is substantially lower, which may diminish the relative impact of antimicrobial interventions.

This context-dependent effectiveness underscores a broader principle in global health: interventions must be tailored not only to biological mechanisms but also to environmental and healthcare system realities. Chlorhexidine’s utility appears closely tied to settings where infection risk is high and access to sterile care is limited.

From a policy perspective, these findings align with existing World Health Organization recommendations, which support chlorhexidine cord care in high-risk environments. At the same time, the review highlights persistent evidence gaps—particularly in high-income settings and for non-chlorhexidine antiseptics—that warrant further investigation.

Ultimately, the updated analysis reinforces chlorhexidine as a low-cost, evidence-based intervention with the potential to reduce neonatal infections and possibly mortality where the burden is greatest. Its impact, however, is not universal, reminding clinicians and policymakers alike that even the most straightforward interventions must be applied with careful attention to context.